Deri Testleri ve İnterferon Gama Salınım Testleri

Authors

Süheyla Sürücüoğlu
https://orcid.org/0000-0001-8545-3364
Nalan Sürücüoğlu

References

Global tuberculosis report 2025. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. Accessed May 31, 2026. https://iris.who.int/server/api/core/bitstreams/e97dd6f4-b567-4396-8680-717bac6869a9/content

World Health Organization, ed. WHO Consolidated Guidelines on Tuberculosis: Tuberculosis Preventive Treatment; Module 1: Prevention. Second edition. World Health Organization; 2024.

Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642-1656. doi:10.1016/S0140-6736(19)30308-3

Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738. doi:10.1136/bmj.k2738

Drain PK, Bajema KL, Dowdy D, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev. 2018;31(4):e00021-18. doi:10.1128/CMR.00021-18

Tuberkuloz_Tani_ve_Tedavi_Rehberi_2026.pdf. Accessed May 31, 2026. https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz-db/Dokumanlar/Rehberler/Tuberkuloz_Tani_ve_Tedavi_Rehberi_2026.pdf

Horsburgh CR, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364(15):1441-1448. doi:10.1056/NEJMcp1005750

Pai M, Behr M. Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiol Spectr. 2016;4(5):10.1128/microbiolspec.tbtb2-0023-2016. doi:10.1128/microbiolspec.tbtb2-0023-2016

Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, Torres M. Diagnosis for Latent Tuberculosis Infection: New Alternatives. Front Immunol. 2020;11:2006. doi:10.3389/fimmu.2020.02006

Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev. 2014;27(1):3-20. doi:10.1128/CMR.00034-13

WHO operational handbook on tuberculosis. Module 3: diagnosis. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. ISBN 978-92-4-011099-1. Accessed May 31, 2026. https://iris.who.int/server/api/core/bitstreams/c50271a9-05ab-4fe5-be18-a11f3d866369/content

Haas MK, Belknap RW. Diagnostic Tests for Latent Tuberculosis Infection. Clin Chest Med. 2019;40(4):829-837. doi:10.1016/j.ccm.2019.07.007

Weyer K, Gilpin C, Mirzayev F, Gemert W van. Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- and Middle-Income Countries: Policy Statement. World Health Organization; 2011.

Migliori GB, Ong CWM, Petrone L, D’Ambrosio L, Centis R, Goletti D. The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe (Sheff). 2021;17(3):210079. doi:10.1183/20734735.0079-2021

WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. ISBN 978-92-4-010798-4.

Hamada Y, Cirillo DM, Matteelli A, Penn-Nicholson A, Rangaka MX, Ruhwald M. Tests for tuberculosis infection: landscape analysis. Eur Respir J. 2021;58(5):2100167. doi:10.1183/13993003.00167-2021

Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192-1204.

Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. Lancet Infect Dis. 2022;22(2):250-264. doi:10.1016/S1473-3099(21)00261-9

Nolt D, Starke JR. Tuberculosis Infection in Children and Adolescents: Testing and Treatment. Pediatrics. 2021;148(6):e2021054663. doi:10.1542/peds.2021-054663

Bergstedt W, Tingskov PN, Thierry-Carstensen B, et al. First-in-Man Open Clinical Trial of a Combined rdESAT-6 and rCFP-10 Tuberculosis Specific Skin Test Reagent. PLOS ONE. 2010;5(6):e11277. doi:10.1371/journal.pone.0011277

Gong W, Wu X. Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy. Front Microbiol. 2021;12:745592. doi:10.3389/fmicb.2021.745592

Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):e1-e33. doi:10.1093/cid/ciw694

Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int J Infect Dis. 2022;124 Suppl 1:S12-S19. doi:10.1016/j.ijid.2022.02.047

Utegenova A, Kassayeva L, Turdalina B, et al. Early Mycobacterial Antigens in the Immunodiagnosis of Latent Tuberculosis Infection. Pathogens. 2026;15(2):181. doi:10.3390/pathogens15020181

Won D, Park JY, Kim HS, Park Y. Comparative Results of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus Assays for Detection of Tuberculosis Infection in Clinical Samples. J Clin Microbiol. 2020;58(4):e01854-19. doi:10.1128/JCM.01854-19

Buonsenso D, Delogu G, Del Carmen Pereyra Boza M, et al. Commercially available CD4 + and CD8 + IFN-γ release assays combined with an HBHA-induced IGRA improve the characterization of the tuberculosis spectrum and monitoring of treatment in children. Eur J Pediatr. 2023;182(5):2155-2167. doi:10.1007/s00431-023-04844-1

Shafeque A, Bigio J, Hogan CA, Pai M, Banaei N. Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence? J Clin Microbiol. 2020;58(9):e01950-19. doi:10.1128/JCM.01950-19

Lee JK, Lee HW, Heo EY, Yim JJ, Kim DK. Comparison of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube tests for patients with active and latent tuberculosis: A prospective cohort study. J Infect Chemother. 2021;27(12):1694-1699. doi:10.1016/j.jiac.2021.08.003

Mahmoudi S, Hamidi M, Drain PK. Present outlooks on the prevalence of minimal and subclinical tuberculosis and current diagnostic tests: A systematic review and meta-analysis. J Infect Public Health. 2024;17(9):102517. doi:10.1016/j.jiph.2024.102517

Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med. 2021;385(24):2271-2280. doi:10.1056/NEJMcp2108501

Wang MS, Li-Hunnam J, Chen YL, et al. Conversion or Reversion of Interferon γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-analysis. Clin Infect Dis. 2025;80(1):168-179. doi:10.1093/cid/ciae357

Guo X, Dong Y, Cai S, et al. Repeat testing or additional tuberculin skin tests for management of indeterminate results of interferon-gamma release assays: a systematic review and meta-analysis. BMC Infect Dis. 2025;25(1):1486. doi:10.1186/s12879-025-11834-1

Yamasue M, Komiya K, Usagawa Y, et al. Factors associated with false negative interferon-γ release assay results in patients with tuberculosis: A systematic review with meta-analysis. Sci Rep. 2020;10(1):1607. doi:10.1038/s41598-020-58459-9

Araújo-Pereira M, Andrade BB. Toward tuberculosis elimination strategy: the role of IGRA on immunocompetent individuals. Int J Infect Dis. Published online March 2026:108518. doi:10.1016/j.ijid.2026.108518

Testing and Treatment of Latent Tuberculosis Infection in the United States NSTC/NTCA Clinical Guide for health care providers and public health programs. Third edition, Updated February 2025. https://tbcontrollers.org/docs/NSTC/LTBI_Clinical_Guide_Feb2025_FINAL.pdf.

Sriram S, Abualfaraj T, Alsharif MA, et al. Comparative Diagnostic Performance of TST and IGRAs in the Diagnosis of Latent Tuberculosis Infection: A Systematic Review and Diagnostic Meta-Analysis. Diagnostics. 2026;16(6):951. doi:10.3390/diagnostics16060951

Kestler B, Tyler SK. Latent tuberculosis testing through the ages: the search for a sleeping killer. Am J Physiol Lung Cell Mol Physiol. 2022;322(3):L412-L419. doi:10.1152/ajplung.00217.2021

Chen H, Nakagawa A, Takamori M, et al. Diagnostic accuracy of the interferon-gamma release assay in acquired immunodeficiency syndrome patients with suspected tuberculosis infection: a meta-analysis. Infection. 2022;50(3):597-606. doi:10.1007/s15010-022-01789-9

Debulpaep S, Overschelde H, Pieters L, et al. The diagnostic accuracy of interferon-gamma release assay for TB infection in children under 5 years: a systematic review with meta-analysis. Int J Tuberc Lung Dis 2026;30:147-155. doi:10.5588/ijtld.25.0341

Zhou G, Luo S, He J, et al. Risk of progression to active tuberculosis for indeterminate interferon-gamma release assay in immunocompromised individuals: a systematic review and meta-analysis. Clin Microbiol Infect. 2023;29(11):1375-1384. doi:10.1016/j.cmi.2023.07.003

Ma Y, Xu Y, Cao X, Chen X, Zhong Y. Diagnostic value of interferon-γ release assay in HIV-infected individuals complicated with active tuberculosis: a systematic review and meta-analysis. Epidemiol Infect. 2021;149:e204. doi:10.1017/S0950268821001953

Zhou G, Luo Q, Luo S, et al. Positive rates of interferon-γ release assay and tuberculin skin test in detection of latent tuberculosis infection: A systematic review and meta-analysis of 200,000 head-to-head comparative tests. Clin Immunol. 2022;245:109132. doi:10.1016/j.clim.2022.109132

Sharma GK, Haq F, Totten AH, Marcos LA, Vorkas CK. Demographic and clinical correlates of discordant QuantiFERON TB Gold tuberculosis screening results in a low-incidence setting. Microbiol Spectr. 14(3):e02822-25. doi:10.1128/spectrum.02822-25

Dorman SE, Belknap R, Graviss EA, et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189(1):77-87. doi:10.1164/rccm.201302-0365OC

Lalvani A, Fraser C, Pareek M. Diagnosis of latent tuberculosis infection. In: Freidman LN, Dedicoat M, Davies PDO (eds), Clinical Tuberculosis. 6th ed. Taylor and Francis Group, Florida; 2020, p. 153-171.

Published

November 17, 2026

License

License